Resverlogix Corp. (RVXCF) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Calgary, AB, Canada. The current CEO is Donald J. McCaffrey.
RVXCF has IPO date of 2009-02-13, 19 full-time employees, listed on the Other OTC, a market capitalization of $25.23M.
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada. The company is headquartered in Calgary, Canada.
